Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma

Supritha, G. S. and Vivek, H. K. and Shubha, Priya B. and Looi, Chung Yeng and Shanmugam, Muthu K. and Arfuso, Frank and Dharmarajan, Arunasalam and Sethi, Gautam and Shivananju, N. S. and Anupam Bishayee, (2017) Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Targeted Oncology, 12 (1). pp. 1-10. ISSN 1776-260X

Full text not available from this repository. (Request a copy)
Official URL: https://doi.org/10.1007/s11523-016-0452-7

Abstract

Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted drug for HCC patients. However, due to adverse side effects and limited efficacy, there is a need for the identification of novel pharmacological drugs beyond sorafenib. Several agents that target and inhibit various signaling pathways involved in HCC are currently being assessed for HCC treatment. In the present review article, we summarize the diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy.

Item Type: Article
Additional Information: Unmapped bibliographic data: JO - Targeted Oncology [Field not mapped to EPrints]
Subjects: Physical Sciences > Chemistry
Divisions: PG Campuses > Manasagangotri, Mysore > Chemistry
Depositing User: Praveen Kumari B.L
Date Deposited: 26 Aug 2017 09:06
Last Modified: 26 Aug 2017 09:06
URI: http://eprints.uni-mysore.ac.in/id/eprint/19867

Actions (login required)

View Item View Item